Tanya Dorff, MD
Medical Oncology · Duarte, CANPI 1508879115
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $89,667 of the $136,404 with a category attached, or 65.7%. 35 manufacturers reported payments, led by Bayer at 25.0% of the total.
Across 206 payments — averaging $662.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$34K
- Exelixis Inc.$14K
- Sanofi$11K
- E.r. Squibb & Sons, L.L.C.$9K
- AstraZeneca$9K
- Astellas Pharma Global Development$9K
- plus $51K from 29 others
Across 407 payments — averaging $21,190 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4.3M
- Merck$1.1M
- Pfizer$833K
- AbbVie$514K
- Janssen Research & Development, LLC$456K
- Genentech, Inc.$365K
- plus $1.1M from 9 others
What the payments were for
- Consulting fees$89,66766%
- Speaking & faculty fees$23,27617%
- Travel & lodging$14,95011%
- Food & beverage$7,7386%
- Education$2730%
- Charitable contribution$5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 34 | $34,097 |
| Exelixis Inc. | 16 | $14,147 |
| Sanofi | 8 | $11,496 |
| E.r. Squibb & Sons, L.L.C. | 7 | $8,778 |
| AstraZeneca | 11 | $8,751 |
| Astellas Pharma Global Development | 4 | $8,633 |
| AbbVie | 9 | $7,659 |
| Seagen Inc. | 14 | $7,263 |
| Pfizer | 18 | $6,868 |
| Advanced Accelerator Applications | 4 | $5,056 |
| Janssen Scientific Affairs, LLC | 6 | $3,215 |
| Astellas Pharma Europe Ltd | 1 | $2,813 |
| Blue Earth Diagnostics | 2 | $2,759 |
| Merck | 7 | $2,257 |
| Sanofi-aventis U.S. LLC | 2 | $1,870 |
| Janssen Global Services, LLC | 2 | $1,831 |
| Johnson & Johnson | 7 | $1,756 |
| Telix Pharmaceuticals | 3 | $1,361 |
| Novartis | 6 | $1,042 |
| Astellas Pharma US Inc | 2 | $1,031 |
| Janssen Research & Development, LLC | 1 | $1,000 |
| Astellas US LLC | 1 | $938 |
| Sumitomo Pharma America, Inc. | 6 | $466 |
| Dendreon Pharmaceuticals LLC | 16 | $438 |
| Bayer Healthcare LLC | 2 | $216 |
| Ferring Pharmaceuticals Inc. | 4 | $155 |
| Progenics Pharmaceuticals, Inc. | 1 | $124 |
| EMD Serono, Inc. | 2 | $81 |
| Teleflex LLC | 3 | $69 |
| Genentech USA, Inc. | 1 | $61 |
| Eisai Inc. | 2 | $55 |
| Fennec Pharmaceuticals, Inc. | 1 | $51 |
| Gilead | 1 | $32 |
| Tempus AI, Inc | 1 | $21 |
| Myovant Sciences Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,404 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 144 | $2,052,929 |
| NubeqaDarolutamide | 173 | $1,963,588 |
| OrgovyxRelugolix | 347 | $899,625 |
| Abiraterone Acetate | 233 | $533,913 |
| CabometyxCabozantinib S-Malate | 20 | $484,079 |
| LynparzaOlaparib | 23 | $291,838 |
| ErleadaApalutamide | 22 | $265,131 |
| EliquisApixaban | 27 | $25,026 |
| Prednisone | 173 | $902 |
| Tamsulosin Hcl | 11 | $321 |
| Ondansetron Hcl | 14 | $290 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $192 |
| Gabapentin | 18 | $144 |
| Enalapril Maleate | 12 | $72 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $1,031 | $2,052,929144 claims |
| BayerNubeqa | $34,097 | $1,963,588173 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $466 | $899,625347 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,215 | $533,913233 claims |
| Exelixis Inc.Cabometyx | $14,147 | $484,07920 claims |
| AstraZenecaLynparza | $8,751 | $291,83823 claims |
| Johnson & JohnsonErleada | $1,756 | $265,13122 claims |
| PfizerEliquis | $6,868 | $25,02627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Daneng LiDuarte$467K
- Howard WestDuarte$426K
- Christine LovlyDuarte$362K
- Marwan FakihDuarte$203K
- Erminia MassarelliDuarte$176K
- Ravi SalgiaDuarte$142K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.